Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT2-SCT for Type 2 Diabetes Mellitus
NCT06789302Phase 2Not yet recruiting
- Sponsor
- GIOSTAR
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Mesenchymal Stem Cells
01
Overview
A Phase 2 trial of DT2-SCT in type 2 diabetes mellitus (T2DM), sponsored by GIOSTAR. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
DT2-SCT
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06789302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789302.